Premium
Copper Catalysis in Living Systems and In Situ Drug Synthesis
Author(s) -
Clavadetscher Jessica,
Hoffmann Scott,
Lilienkampf Annamaria,
Mackay Logan,
Yusop Rahimi M.,
Rider Sebastien A.,
Mullins John J.,
Bradley Mark
Publication year - 2016
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201609837
Subject(s) - bioconjugation , cycloaddition , fluorophore , copper , catalysis , combinatorial chemistry , azide , chemistry , click chemistry , alkyne , in situ , nanotechnology , organic chemistry , materials science , fluorescence , physics , quantum mechanics
The copper‐catalyzed azide–alkyne cycloaddition (CuAAC) reaction has proven to be a pivotal advance in chemical ligation strategies with applications ranging from polymer fabrication to bioconjugation. However, application in vivo has been limited by the inherent toxicity of the copper catalyst. Herein, we report the application of heterogeneous copper catalysts in azide–alkyne cycloaddition processes in biological systems ranging from cells to zebrafish, with reactions spanning from fluorophore activation to the first reported in situ generation of a triazole‐containing anticancer agent from two benign components, opening up many new avenues of exploration for CuAAC chemistry.